一分钟看懂
这是一项关于恶性肿瘤的II 期研究，登记的药物或干预包括RNK08954，当前状态为尚未开始招募。登记地点显示中国上海有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
RNK08954 · II 期
登记条件中文摘要
年龄范围：18岁及以上
登记的基本范围为女性，年龄18岁及以上；以下仅摘录8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Fudan University Shanghai Cancer Center · 上海
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- * Subjects must voluntarily agree to participate in the trial and sign a written informed consent form.
- * Age ≥ 18 years, female.
- * Physical condition score ECOG score 0-1 points.
- * Expected survival ≥ 12 weeks.
- * At the time of study enrollment, according to the solid tumor efficacy evaluation criteria (RECIST1.1), imaging diagnosis had at least one measurable lesion.
- * Have adequate hematologic and end-organ function, with laboratory test results within required parameters within 7 days prior to the first dose.
- * Histologically or cytologically confirmed advanced gynecological malignancy (including ovarian cancer, endometrial cancer, cervical cancer, etc.) with disease progression after at least one prior systemic therapy.
- * Presence of a KRAS G12D mutation.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07848893；登记信息更新于 2026-09-30；本站同步于 2026-10-08。